Specialists mentioned stock correction, product cycle timing, and above-normal shopping for in March 2025 forward of tariffs have additionally created a excessive base that present shipments wrestle to match.
“Provided that FY26 closed at $9.47 billion with a ten% drop and March 2026 got here in down one other 10% year-on-year, pharma exports to the US in April-Could 2026 are more likely to present a flat-to-negative print except the stock correction ended sooner than anticipated,” pharma skilled Dinesh Dua mentioned.
The commerce ministry is anticipated to launch detailed commerce knowledge on June 15.
Additionally Learn: Aurobindo Pharma enters biologics contract manufacturing with Rs 1,200-crore Telangana facility
Specialists additionally level to a structural shift quietly underway on the American facet. In line with an skilled, US distributors and hospital networks are more and more managing inventories extra tightly, putting orders nearer to precise consumption relatively than constructing giant buffers.
“Compounding this, the push to encourage native pharma manufacturing within the US, given recent political momentum by the present administration, threatens to steadily erode the amount benefit that Indian generics makers have lengthy loved,” mentioned an skilled on the situation of anonymity.The coverage entrance has added recent anxiousness. “Govt orders by the administration have dampened sentiment and slowed recent orders in April and Could.”
Business our bodies have flagged that even the place tariffs don’t straight apply, the regulatory unpredictability itself is sufficient to make patrons cautious about putting giant ahead orders.
The US stays India’s single largest pharma export vacation spot accounting for roughly 30% of the overall shipments. Indian drugmakers, notably these closely uncovered to the American generics market, have seen margins squeezed from each ends-falling realisations on one facet, and rising compliance and logistics prices on the opposite.
